Pharmacoepidemiological study of oxaliplatin safety (analysis of Russian spontaneous reporting database)

Close metadata

OBJECTIVE

To assess oxaliplatin safety considering spontaneous adverse reaction (AR) reports and oxaliplatin consumption.

MATERIAL AND METHODS

Spontaneous AR reports with high cause-and-effect relations were obtained from the «Pharmacovigilance» subsystem of Roszdravnadzor’s automated information system (2015—2023). We excluded duplicate and non-valid reports. We assessed ARs after oxaliplatin therapy according to registered indications and off-label treatment, as well as original and generic oxaliplatin.

RESULTS. A

Nalysis included 715 spontaneous AR reports where oxaliplatin was used for registered indications (colorectal cancer — 53.4%, ovarian cancer — 1.4%) and in off-label fashion (26%). The overall AR spectrum corresponded to known safety profile without new safety data. In oxaliplatin therapy for registered indications, the highest proportions of ARs were observed for immune (21%), respiratory (18.4%), nervous (10.4%) and vascular systems (12.3%), as well as skin (10.9%), gastrointestinal tract (9.2%), and blood (7.1%). Differences in AR frequency among system classes were attributed to the nature of spontaneous AR reporting. Off-label therapy demonstrated lower incidence of adverse reactions in immune and respiratory systems, as well as higher incidence of reactions in blood and gastrointestinal tract compared to registered indications. Adverse reactions following original oxaliplatin were comparable to that for generic drugs.

CONCLUSION

Extensive research of oxaliplatin safety profile has been previously conducted. There were no new safety data. ARs varied depending on indications (registered or off-label) but were independent of whether it was original or generic products.

Keywords:

oxaliplatin

safety analysis

adverse reactions

real-world clinical practice

Authors:

Gopienko I.A.

Patrice Lumumba Peoples’ Friendship University of Russia

ORCID: 0000-0003-3089-1804

Zyryanov S.K.

Patrice Lumumba Peoples’ Friendship University of Russia;
Moscow City Clinical Hospital No. 24

ORCID: 0000-0002-6348-6867

Received:

17.04.2024

Accepted:

20.05.2024

List of references:

Soulié P, Raymond E, Brienza S, Cvitkovic E. Oxaliplatin: the first DACH platinum in clinical practice. Bulletin du Cancer. 1997;84(6): 665-673.
Cheng J, Shuai X, Gao J, Wang G, Tao K, Cai K. Comparative efficacy and tolerability of adjuvant systemic treatments against resectable colon cancer: a network meta-analysis. Therapeutic Advances in Medical Oncology. 2020;14(12):1758835920974195. https://doi.org/10.1177/1758835920974195
Song JH, Lee JH, Kim SH, Um JW; Korean Clinical Practice Guideline for Colon, Rectal Cancer Committee. Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis. International Journal of Colorectal Disease. 2022;37:649-656. https://doi.org/10.1007/s00384-022-04096-9
Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA Drug Approval Summaries: Oxaliplatin. The Oncologist.2004;9(1):8-12. https://doi.org/10.1634/theoncologist.9-1-8
Klinicheskie rekomendatsii. Agressivnye nefollikulyarnye limfomy — diffuznaya krupnokletochnaya B-kletochnaya limfoma, pervichnaya mediastinal’naya B-kletochnaya limfoma, limfoma Berkitta. 2020. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/129
Klinicheskie rekomendatsii. Limfoma marginal’noj zony. 2023. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/137
Klinicheskie rekomendatsii. Rak podzheludochnoj zhelezy. 2021. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/355
Klinicheskie rekomendatsii. Rak pecheni (gepatotsellyulyarnyj). 2022. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/1
Klinicheskie rekomendatsii. Rak zheludka. 2020. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/574
Klinicheskie rekomendatsii. Rak pishchevoda i kardii. 2021. (In Russ.). Accessed March 06, 2024. https://cr.minzdrav.gov.ru/recomend/237
Baratelli C, Zichi C, Di Maio M, Brizzi MP, Sonetto C, Scagliotti GV, Tampellini M. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Critical Reviews in Oncology/Hematology. 2018;122:21-29. https://doi.org/10.1016/j.critrevonc.2017.12.010
Yu Z, Huang R, Zhao L, Wang X, Shangguan X, Li W, et al. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Frontiers in Oncology. 2021;11:757196. https://doi.org/10.3389/fonc.2021.757196
Grothey A. Oxaliplatin-safety profile: neurotoxicity. Seminars in Oncology. 2003;30(4 Suppl 15):5-13. https://doi.org/10.1016/S0093-7754(03)00399-3
Bogliolo S, Cassani C, Gardella B, Musacchi V, Babilonti L, Venturini P-L, et al. Oxaliplatin for the treatment of ovarian cancer. Expert Opinion on Investigational Drugs. 2015;24(9):1275-1286. https://doi.org/10.1517/13543784.2015.1062874
Zhao G, Gao P, Yang KH, Tian JH, Ma B. Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. Colorectal Disease. 2010;12(7):615-623. https://doi.org/10.1111/j.1463-1318.2009.01879.x
Kolomeytseva AA, Kopachevskaia SV, Orel NF, Gorbunova VA, Eskina TY, Fedyanin MY, et al. The comparison of the therapeutic equivalence of Oxaliplatin-ronc (branch «Naukoprofi» of NN. Blokhin RCRC) and Eloxatin (Aventis Pharma ltd, Great Britain) in mFOLFOX6 combination as a first line of chemotherapy in patients with metastatic colorectal cancer. Zlokachestvennye opukholi. 2016;(4):58-67. (In Russ.). https://doi.org/10.18027/2224-5057-2016-4-58-67
Urmancheeva AF. Oksaliplatin (Eloksatin) v lechenii metastaticheskogo raka yaichnika. RMZh. Prilozhenie. Onkologiya. 2010; 1(1):6-12. (In Russ.).
Litvinenko TS, Safronenko AV, Maklyakov YS, Gantsgorn EV, Postnikova ES, Gaisaev MO, Brizhak VG. Analysis of Spontaneous Reports as a Methodological Pharmacovigilance Tool. Journal Biomedicine. 2022;18(2):40-45. (In Russ.). https://doi.org/10.33647/2074-5982-18-2-40-45
Karabina EV, Sakaeva DD, Lipatov ON. Off-label drug use in oncology. Creative Surgery and Oncology. 2022;12(2):164-171. (In Russ.). https://doi.org/10.24060/2076-3093-2022-12-2-164-171
Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, et al. Safety and evidence of off-label use of approved drugs at the national cancer center hospital in Japan. JCO Oncology Practice. 2021;17(3):e416-425. https://doi.org/10.1200/OP.20.00131
Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: Definitions and clarification of terminology. British Journal of Clinical Pharmacology. 2017;83(12):2615-2625. https://doi.org/10.1111/bcp.13394
Gataullin BI. Gender features of colorectal cancer. A review of the literature. Oncology Bulletin of the Volga Region. 2020;11(2):37-42. (In Russ.).

Close metadata